Glaukos Corporation (GKOS) Tops Q3 EPS by 5c; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Glaukos Announces Third Quarter 2023 Financial Results
November 1, 2023 4:05 PM EDTALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2023. Key highlights include:
Net sales of $78.0 million in Q3 2023 increased 10% year-over-year on a reported basis and 9% year-over-year on a constant currency basis. Glaucoma net sales of $58.3 million in Q3 2023 increased 9% year-over-year. Corneal Health net sales of $19.7 million in Q3 2023 increased 12% year-over-year. Gross margin of approximately 76%... More